In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
|Podcasts|July 5, 2023
Achieving Durable Clinical Response with Targeted Treatments for Vitiligo
Listen
0:00 / 0:00
In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.
Advertisement
0:53 Quality of life impact of vitiligo
2:55 Pathogenesis of vitiligo
5:08 Approaches to vitiligo treatment
8:30 Mechanism of JAK inhibitors
10:25 TRuE-V1 and TRuE-V2 studies for the JAK inhibitor ruxolitinib
14:15 Variation in repigmentation with vitiligo
17:20 Safety of topical ruxolitinib
21:00 Data from the long-term extension trial of ruxolitinib
25:75 Achieving meaningful treatment response in vitiligo
30:15 Investigational biomarkers and treatments for vitiligo
Advertisement
Related to this article
In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.
New ASH guidelines recommend higher ferritin thresholds to improve the diagnosis of iron deficiency across key populations.
In this Q&A, Alysse Wurcel, MD, translates qualitative barriers into 8 concrete tactics healthcare practices can use to expand penicillin allergy delabeling.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
BEACON-HCC offers a new approach to HCC treatment allocation, with key differences from the updated BCLC framework.
Advertisement
Advertisement
Trending on HCPLive
1
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
2
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
3
Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data
4
Immediate Coronary Angiography Does Not Improve Survival Outcomes in Cardiac Arrest
5